GT Biopharma, Inc. Overview
Pro stress-test →GT Biopharma is a clinical-stage immuno-oncology company focused on developing innovative therapies based on its proprietary NK cell engager (TriKE®) technology. The TriKE platform is designed to harness and enhance the cancer-killing abilities of a patient's immune system's natural killer cells.
Strategic Profile
Pro stress-test →Its lead clinical candidate, GTB-3650, is in a Phase 1 dose-escalation trial for relapsed or refractory CD33-expressing hematologic malignancies, while GTB-5550 targets B7-H3–expressing solid tumors and has reached the IND submission stage. However, in November 2025, the company received a Nasdaq notice that its common stock had closed below $1 per share for 30 consecutive business days, indicating non-compliance with the minimum bid price requirement for continued listing.
Competitive Landscape
Pro stress-test →GT Biopharma operates in the NK cell-based immunotherapy segment, competing with other emerging biotech firms developing engineered NK and T-cell platforms. Direct competitors include Fate Therapeutics and Juno Therapeutics (Celgene/Bristol Myers Squibb subsidiary), though GT's TriKE approach differs from traditional CAR-NK and CAR-T modalities. The company faces competition from larger pharmaceutical immunotherapy programs at Merck, Roche, and others pursuing similar oncology indications.
Industry Context
GT Biopharma, Inc. operates in NK cell-based immunotherapy.
Key facts
Founded: 1998 (as OXIS International) · Headquarters: San Francisco, US · Employees: Unknown · Revenue: Null · Market cap: ~$0.09B (based on June 2026 stock price ~$0.42)